Physician-Scientist, Inventor, Author, TEDx Speaker, and Serial Entrepreneur
Seattle, WA
Joined April 2009
- Tweets255
- Following111
- Followers2.1K
- Likes16
Steven Quay, MD, PhD retweeted
Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment” dlvr.it/Sn99Cg
Steven Quay, MD, PhD retweeted
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update dlvr.it/SlKMXw
Steven Quay, MD, PhD retweeted
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial dlvr.it/SlGLbz
Steven Quay, MD, PhD retweeted
Atossa to Present at the Sidoti Small-Cap Virtual Conference dlvr.it/Sky54D
Steven Quay, MD, PhD retweeted
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer dlvr.it/SjtWjj
Steven Quay, MD, PhD retweeted
Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen dlvr.it/SjLzvT
Steven Quay, MD, PhD retweeted
Atossa Therapeutics Issues Letter to Shareholders dlvr.it/ShQpQT
Steven Quay, MD, PhD retweeted
Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations dlvr.it/Sf0XTW
Steven Quay, MD, PhD retweeted
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update dlvr.it/ScPZtT
Steven Quay, MD, PhD retweeted
Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy dlvr.it/Sc3Nmw
Steven Quay, MD, PhD retweeted
Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer dlvr.it/SbfXHh
Steven Quay, MD, PhD retweeted
Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference dlvr.it/SbfXHd
Steven Quay, MD, PhD retweeted
Registration Now Open for Tribe Public’s Webinar Event “The Important Role For Inhalation Therapy In Oncology” Featuring The Management Team From Atossa Therapeutics on August 25, 2022 dlvr.it/SbfXHb
Steven Quay, MD, PhD retweeted
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board dlvr.it/SbfXHS
Steven Quay, MD, PhD retweeted
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update dlvr.it/SbfXGx
Steven Quay, MD, PhD retweeted
Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer dlvr.it/Sbd0Bn
Steven Quay, MD, PhD retweeted
Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference dlvr.it/SXwC6b
Steven Quay, MD, PhD retweeted
Registration Now Open for Tribe Public’s Webinar Event “The Important Role For Inhalation Therapy In Oncology” Featuring The Management Team From Atossa Therapeutics on August 25, 2022 dlvr.it/SX2st8
Steven Quay, MD, PhD retweeted
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board dlvr.it/SWrVng
Steven Quay, MD, PhD retweeted
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update dlvr.it/SWHQ3X